CyberKnife is one of multiple modalities for stereotactic radiosurgery (SRS). Due to the nature of CyberKnife and the characteristics of SRS, dose evaluation of the CyberKnife procedure is critical. A radiophotoluminescent glass dosimeter was used to verify the dose accuracy for the CyberKnife procedure and validate a viable dose verification system for CyberKnife treatment. A radiophotolumines...

Background: Radiotherapy, as a therapeutic option, has a limited role for the treatment of HCC, but, cyberknife is a newly developed hypofractionated stereotactic body radiation therapy (SBRT). The objective of this retrospective study was to evaluate the efficacy of cyberknife compared with conventional radiotherapy for the patients with advanced HCC. Methods: We retrospectively reviewed the m...

PURPOSE To assess prostate-specific antigen (PSA) kinetics and report on the oncologic outcomes for patients with localized prostate cancer treated with stereotactic body radiation therapy (SBRT) using CyberKnife. METHODS We extracted the list and data of 39 patients with clinically localized prostate cancer who had undergone primary SBRT using CyberKnife between January 2008 and December 201...

Lancaster General Health is the first institution in the United States to have the next generation CyberKnife made by Accuray Inc., the M6 series (Fig. 1). The CyberKnife utilizes non-invasive stereotactic radiosurgery to deliver precise, high doses of radiation to targets anywhere in the body. Recent studies have shown that stereotactic radiosurgery offers high rates of tumor control with mini...

INTRODUCTION The current standard for treating operable early stage non-small cell lung cancer is surgical resection and for inoperable cases it is external beam radiotherapy. Lung functions are adversely affected with both the above treatments. CyberKnife treatment limits radiation damage by tracking targets moving with each breath. The effect of CyberKnife treatment on pulmonary function test...

The aim of this study is to compare the dosimetric characteristics of robotic and conventional linac-based SBRT techniques for lung cancer, and to provide planning guidance for each modality. Eight patients who received linac-based SBRT were retrospectively included in this study. A dose of 60 Gy given in three fractions was prescribed to each target. The Synchrony Respiratory Tracking System a...

Acceptance testing and commissioning of a CyberKnife robotic stereotactic radiosurgery system was performed in April 2006. The CyberKnife linear accelerator produces a photon beam of 6 MV nominal energy, without the use of a flattening filter. Clinically measured tissue-phantom ratios, off-center ratios, and output factors are presented and compared with similar data from other CyberKnife sites...

Accuray Inc. (Sunnyvale, CA) designs, develops, and sells the CyberKnife Stereotactic Radiosurgery System, an image-guided radiosurgical instrument used to ablate diverse benign and malignant lesions. In 2001, Accuray received clearance from the Food and Drug Administration (FDA) to market the CyberKnife for radiosurgical treatment of lesions anywhere in the body where radiation is indicated. S...

PURPOSE To examine and facilitate the feasibility of the ArcCheck cylindrical diode array system as a patient specific QA device for CyberKnife radiosurgery delivery. METHODS There is an obvious necessity for CyberKnife robotic radiosurgery patient QA procedures for hypofractionated treatment of larger planned treatment volumes (PTV), e.g. prostate. This need will increase when the future Cyb...

Accuray Incorporated designs, develops and sells the CyberKnife Stereotactic Radiosurgery System, an image-guided radiosurgical instrument used to ablate diverse benign and malignant lesions. In 2001, Accuray received clearance from the Food and Drug Administration (FDA) to market the CyberKnife for radiosurgical treatment of lesions anywhere in the body where radiation is indicated. From its i...